Kiyosshi Matsui

Prof. Kiyosshi Matsui

Hyogo Medical University Hospital, Nishinomiya, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
THTEPPEI HASHIMOTO
TEPPEI HASHIMOTO
KYKohsuke Yoshida
Kohsuke Yoshida
AHAkira Hashiramoto
Akira Hashiramoto
KMKiyosshi Matsui
Kiyosshi Matsui
Endogenous DNA derived from the nuclei or mitochondria is released into the bloodstream following cell damage or death. Extracellular DNA, called cell-free DNA (cfDNA), is associated with various pathological conditions. Recently, multiple aspects of cfDNA have been assessed, including cfDNA levels, integrity, methylation, and mutations. Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, and treatment of RA has highly varied outcomes. cfDNA in patients with RA is elevated in peripheral blood and synovial fluid and is associated with disease activity. Profiling of cfDNA in patients with RA may then be utilized in various aspects of clinical practice, such as the prediction of prognosis and treatment responses; monitoring disease state; and as a diagnostic marker. In this review, we discuss cfDNA in patients with RA, particularly the sources of cfDNA and the correlation of cfDNA with RA pathogenesis. We also highlight the potential of analyzing cfDNA profiles to guide individualized treatment approaches for RA.

Verified
Journal Article
Open access
PDF file
KMKiyosshi Matsui
Kiyosshi Matsui
HSHajime Sano
Hajime Sano
Primary Sjögren’s syndrome is an autoimmune disease characterized by diffuse infiltration of lymphocytes into exocrine glands and other tissues. The infiltrating lymphocytes have been identified as subsets of B cells and T cells, including T helper 17 cells, T regulatory cells and follicular helper T cells. The role of these cells in the development of the syndrome is now known, as is their impact on the production of proinflammatory cytokines such as IL-6, IL-17, IL-22 and IL-23. In particular, experimental animal models and patients suggest that a shift in Th17/Treg balance toward the proinflammatory Th17 axis exacerbates primary Sjögren’s syndrome and other autoimmune disorders. Nevertheless, the pathogenesis of the disorder is not yet fully elucidated. This review summarizes the recent advances in therapeutic control of the Treg/Th17 balance, as well as the efficacy of candidate therapeutics against primary Sjögren’s syndrome.

6 September 2018 in Modern Rheumatology
Verified
Journal Article
Closed access
TFTetsuya Furukawa
Tetsuya Furukawa
KMKiyosshi Matsui
Kiyosshi Matsui
MKMasayasu Kitano
Masayasu Kitano
YYYuichi Yokoyama
Yuichi Yokoyama
MSMasahiro Sekiguchi
Masahiro Sekiguchi
HSHajime Sano
Hajime Sano
Objectives: Systemic sclerosis (SSc) is an intractable connective tissue disease that causes skin and organ fibrosis. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) affect its prognosis. YKL-40 protein impacts inflammation and tissue remodeling. Therefore, we evaluated the utility of YKL-40 blood levels in identifying patients with SSc complicated by PAH, as confirmed by immunohistochemistry (IHC) examination. Methods: We retrospectively analyzed 78 patients with SSc and performed IHC on 7 normal and 7 SSc skin samples in the Japanese population. Age-adjusted YKL-40 serum levels were analyzed. Results: YKL-40 age percentile was significantly elevated in SSc patients. There was no difference between patients with SSc with and without ILD and PAH. YKL-40 age percentile was greater in patients with PAH complication. YKL-40 immunostaining was negative in normal skin and prominent in the subcutaneous vascular wall of all SSc samples. Receiver operating characteristic (ROC) curve analysis indicated that YKL-40 age percentile correctly differentiated between patients with and without PAH with a sensitivity of 80% and a specificity of 94.1%. Conclusion: A higher YKL-40 level with PAH may be reflective of angiogenesis due to capillary injury in SSc. YKL-40 may offer a useful and easily applicable diagnostic biomarker of SSc complicated with PAH.

8 July 2022 in Immunological Medicine
Verified
Journal Article
Open access
KTKazuyuki Tsuboi
Kazuyuki Tsuboi
KNKazuteru Noguchi
Kazuteru Noguchi
MKMasayasu Kitano
Masayasu Kitano
TFTetsuya Furukawa
Tetsuya Furukawa
THTeppei Hashimoto
Teppei Hashimoto
KMKiyosshi Matsui
Kiyosshi Matsui
We examined whether serum B cell activating factor (BAFF) is useful for predicting the remission of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following rituximab treatment. We used the Birmingham Vasculitis Activity Score (BVAS) 2008 version 3 for the evaluation of 27 patients with AAV 6 months after rituximab treatment. Those with BVAS = 0 achieved remission, whereas those with BVAS score > 0 did not achieve remission. We considered changes in serum BAFF before rituximab treatment, 1 month after treatment, and 6 months after treatment. In the remission group, the serum BAFF increased consistently. In the non-achieved group, serum BAFF was within the normal range. In addition, there was no statistically significant difference between the two groups in terms of serum BAFF before and 1 month after rituximab treatment. However, the serum BAFF level at 6 months after rituximab treatment was significantly higher in the remission group than in the non-achieved group. If serum BAFF does not increase after 6 months of rituximab in AAV, it may be assumed that there are residual B cells and plasma cells in the tissues. Enhanced treatment targeting B cells, including re-administration of rituximab or the addition of other immunosuppressive drugs, should be considered.

1 January 2018 in Allergology International
Verified
Journal Article
Open access
MTMasao Tamura
Masao Tamura
KMKiyosshi Matsui
Kiyosshi Matsui
YKYukihiro Kobayashi
Yukihiro Kobayashi
COChie Ogita
Chie Ogita
KTKazuyuki Tsuboi
Kazuyuki Tsuboi
HSHajime Sano
Hajime Sano

31 January 2025 in Modern Rheumatology
Verified
Journal Article
Open access
KKKazutaka Kawamori
Kazutaka Kawamori
NONao Oguro
Nao Oguro
KSKunika Shimizu
Kunika Shimizu
TKTakashi Kida
Takashi Kida
SOSatoshi Omura
Satoshi Omura
NYNobuyuki Yajima
Nobuyuki Yajima
Objectives: Cytomegalovirus (CMV) reactivation during immunosuppressive therapy poses a risk of severe infections. This study aimed to investigate the risk factors of CMV reactivation in patients with microscopic polyangiitis and granulomatosis with polyangiitis using a nationwide cohort in Japan. Methods: This retrospective cohort study used data from the Japan Collaborative Registry of antineutrophil cytoplasmic antibody-associated vasculitis. The outcome was as CMV reactivation up to 48 weeks after treatment initiation. We explored the risk factors for CMV reactivation by comparing the two groups. Results: Of the 454 patients, CMV reactivation occurred in 89 (19.6%). The univariate analysis showed that patients with CMV reactivation were older (P < .001), had higher Birmingham Vasculitis Activity Scores (BVAS) (P = .004) and BVAS renal scores (P < .001), and had received glucocorticoid pulse (P = .004). The logistic regression analysis showed that hypoalbuminemia (odds ratio: 0.55, 95% confidence interval: 0.31–0.98), and low serum IgG (OR: 0.94, 95% CI: 0.89–1.00) were risk factors for CMV reactivation. Conclusions: Hypoalbuminemia and low serum IgG levels were risk factors for CMV reactivation. It is necessary to accurately identify high-risk patients and closely monitor their condition.